Vodafone and AstraZeneca disappoint in tough times

Two of Britain's biggest global players have reported disappointing results. AstraZeneca has warned profit and revenue will fall this year as cheap generic versions of its cholesterol drug Crestor continue to hit sales and cut-throat competition in India and an onslaught from rivals in its home market prompted Vodafone to nudge its full-year earnings guidance down. Sonia Legg reports.

Subscribe: http://smarturl.it/reuterssubscribe
More updates and breaking news: http://smarturl.it/BreakingNews

Reuters tells the world's stories like no one else. As the largest international multimedia news provider, Reuters provides coverage around the globe and across topics including business, financial, national, and international news. For over 160 years, Reuters has maintained its reputation for speed, accuracy, and impact while providing exclusives, incisive commentary and forward-looking analysis.

http://reuters.com/
https://www.facebook.com/Reuters
https://plus.google.com/u/0/s/reuters
https://twitter.com/Reuters